Syntara (SNT) investor relations material

Executive summary

• Positive FDA feedback supports advancement of amsulostat into a ~100-patient Phase II-B trial for myelofibrosis, de-risking the asset and providing a clear late-stage development pathway.

• Institutional placement raised AUD 8 million, extending cash runway into FY28 and supporting key clinical milestones and ongoing commercial/licensing discussions.

• Preliminary Phase II results for SNT-4728 show statistically significant reduction in brain inflammation in Parkinson's disease-related regions.

• SNT-9465 Phase 1b hypertrophic scar trial reached 60% recruitment, with completion targeted for Q3 2026.

• Three main programs advanced: amsulostat (myelofibrosis, myelodysplastic syndrome, pancreatic cancer), skin scarring (9465), and Parkinson’s disease (SNT-4728).

Financial highlights

• Institutional placement added AUD 8 million to the balance, with institutional ownership at 44% and major shareholders maintaining or increasing stakes.

• Cash balance at 30 June 2026 was AUD 13.5 million, up from AUD 8.9 million at 31 March 2026.

• Net cash inflow of AUD 4.7 million for the quarter, mainly from AUD 8.8 million raised via placement and share purchase plan.

• Net cash outflows from operating activities were AUD 1.6 million, with R&D and staff costs totaling AUD 3.3 million.

• Market capitalization as of 23 July 2026: AUD 47 million; enterprise value: AUD 33.5 million.

Outlook and guidance

• Preparing to start Phase II-B myelofibrosis trial by year-end, contingent on securing additional funding or partnerships.

• Multiple clinical milestones anticipated in H2 2026, including full SNT-4728 data, amsulostat MDS interim results, and SNT-9465 top-line results.

• Cash runway now extends into FY28, supporting ongoing and upcoming clinical trials.

• Further payments expected from the sale of the mannitol respiratory business, though timing and quantum remain uncertain.